利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

12 条记录 (耗时 0.032 秒)

    Ligand activated transcriptional regulator proteins
    6.
    发明授权
    Ligand activated transcriptional regulator proteins 失效
    配体活化转录调节蛋白

    公开(公告)号：US07442784B2

    公开(公告)日：2008-10-28

    申请号：US10422934

    申请日：2003-04-23

    申请人： Carlos F. Barbas, III ,  Michael Joseph Kadan ,  Roger Beerli

    发明人： Carlos F. Barbas, III ,  Michael Joseph Kadan ,  Roger Beerli

    IPC分类号： C07H21/04 ,  C12P21/06 ,  C12P21/04 ,  C12N15/00 ,  C12N5/00 ,  C12N5/02

    CPC分类号： C12N15/63 ,  A61K48/00 ,  C07K14/4702 ,  C07K14/70567 ,  C07K14/721 ,  C07K2319/00

    摘要： Fusion proteins for use as ligand-dependent transcriptional regulators are provided. The fusion proteins include a nucleotide binding domain operatively linked to a ligand-binding domain. They also can include a transcription regulating domain. The nucleotide binding domain is a zinc-finger peptide that binds to a targeted contiguous nucleotide sequence of from 3 to about 18 nucleotides are provided. The fusion proteins are used for gene therapy. Also provided are polynucleotides encoding the fusion proteins, expression vectors, and transfected cells.

    摘要翻译： 提供用作配体依赖性转录调节子的融合蛋白。 融合蛋白包括可操作地连接到配体结合结构域的核苷酸结合结构域。 它们还可以包括转录调节结构域。 核苷酸结合结构域是提供与约3至约18个核苷酸的靶向连续核苷酸序列结合的锌指肽。 融合蛋白用于基因治疗。 还提供了编码融合蛋白，表达载体和转染细胞的多核苷酸。

    SELECTION OF HUMAN MONOCLONAL ANTIBODIES BY MAMMALIAN CELL DISPLAY
    7.
    发明申请
    SELECTION OF HUMAN MONOCLONAL ANTIBODIES BY MAMMALIAN CELL DISPLAY 审中-公开
    通过MAMMALIAN细胞显示选择人类单克隆抗体

    公开(公告)号：US20100292089A1

    公开(公告)日：2010-11-18

    申请号：US12312372

    申请日：2007-10-26

    申请人： Martin F. Bachmann ,  Monika Bauer ,  Roger Beerli

    发明人： Martin F. Bachmann ,  Monika Bauer ,  Roger Beerli

    IPC分类号： C40B30/04

    CPC分类号： C07K16/00 ,  C07K16/082 ,  C07K16/10 ,  C07K2317/21 ,  C07K2317/55 ,  C07K2317/622 ,  C07K2317/92 ,  C12N15/1037

    摘要： The application provides a method of isolating a eukaryotic cell expressing an antibody of desired specificity, preferably a monoclonal single chain antibody (scFv). The application further provides methods which allow to clone the variable regions of said antibody from that isolated eukaryotic cell and to recombinantly produce antibodies comprising said variable regions as fusion protein with a purification tag, eg. as Fc-fusion, as a Fab fragment, or as whole antibodies, such as IgG, IgE, IgD, IgA and IgM. Said methods also allows to recombinantly produce antibodies with desired specificity in a fully species specific form, preferably as fully human antibodies.

    摘要翻译： 本申请提供了分离表达具有所需特异性的抗体的真核细胞的方法，优选单克隆单链抗体（scFv）。 本申请还提供允许克隆来自该分离的真核细胞的所述抗体的可变区的方法，并重组产生包含所述可变区作为融合蛋白的抗体与纯化标签，例如， 作为Fc融合体，Fab片段，或作为完整抗体，例如IgG，IgE，IgD，IgA和IgM。 所述方法还允许以完全物种特异性形式重组产生具有所需特异性的抗体，优选作为完全人抗体。

    Modified polypeptides for targeting cell-entry of the adenoviruses of subtype b
    9.
    发明申请
    Modified polypeptides for targeting cell-entry of the adenoviruses of subtype b 审中-公开
    用于靶向亚型b的腺病毒细胞进入的修饰多肽

    公开(公告)号：US20070065408A1

    公开(公告)日：2007-03-22

    申请号：US10558279

    申请日：2004-05-27

    申请人： Roger Beerli ,  Martin Bachmann

    发明人： Roger Beerli ,  Martin Bachmann

    IPC分类号： A61K48/00 ,  C07H21/04 ,  C12P21/06 ,  C07K16/30 ,  C07K14/705

    CPC分类号： C07K14/705 ,  A61K38/00 ,  C07K16/46 ,  C07K2319/30 ,  C07K2319/32 ,  C07K2319/33 ,  C07K2319/43 ,  C12N15/62

    摘要： This invention relates to modified polypeptides comprising two functional components: first, a polypeptide derived from the extracellular region of CD46 as a specific binding site for adenoviruses of the subgroup B, and second, a component capable of binding to a cell surface molecule. Such modified polypeptides are able to direct adenovirus infection specifically to cells having said cell surface molecule on their surface. The invention relates to nucleic acid sequences encoding fusion proteins comprising a) a polypeptide derived from the extracellular domain of CD46 and b) a heterologous polypeptide, methods for the production of the modified polypeptides and suitable recombinant expression vectors and host cells. Pharmaceutical compositions comprising the modified polypeptide of the invention are useful together with recombinant, genetically engineered adenovirus of subtype B for the treatment and prophylaxis of disorders and diseases, like cancer.

    摘要翻译： 本发明涉及包含两个功能组分的修饰的多肽：首先，衍生自CD46细胞外区域的多肽作为亚组B的腺病毒的特异性结合位点，其次是能够结合细胞表面分子的组分。 这种修饰的多肽能够将腺病毒感染特异性地引导到其表面上具有所述细胞表面分子的细胞。 本发明涉及编码融合蛋白的核酸序列，其包含a）源自CD46细胞外结构域的多肽和b）异源多肽，产生修饰多肽的方法和合适的重组表达载体和宿主细胞。 包含本发明修饰多肽的药物组合物与B型重组基因工程改造的腺病毒一起可用于治疗和预防疾病和疾病如癌症。